Justin Four - BioLife Sciences CEO Founder
| BLFE Stock | USD 0.0001 0.00 0.00% |
Insider
Justin Four is CEO Founder of BioLife Sciences
| Age | 33 |
| Phone | 833-919-1037 |
| Web | https://www.biolifesciences.com |
Similar Executives
| Showing other executives | INSIDER Age | ||
| Tom Adams | Repro Med Systems | N/A | |
| Alka FACMG | Bionano Genomics | 51 | |
| Yulin Wang | Meihua International Medical | 55 | |
| David BA | GlucoTrack | 59 | |
| Erez BenZvi | GlucoTrack | 46 | |
| Julia Kirshner | Predictive Oncology | N/A | |
| Raymond Vennare | Predictive Oncology | 71 | |
| Barry Berler | Sharps Technology | 70 | |
| Christopher Stewart | Bionano Genomics | 54 | |
| Mark Oldakowski | Bionano Genomics | 50 | |
| Lianzhang Zhao | Meihua International Medical | 56 | |
| Josh Bennett | Repro Med Systems | N/A | |
| Jonathan Dixon | Bionano Genomics | N/A | |
| Robert Hayes | Sharps Technology | 57 | |
| Alan Blackman | Sharps Technology | 75 | |
| Robert MBA | Bionano Genomics | 56 | |
| Esq CPA | GlucoTrack | 59 | |
| DSc OD | Predictive Oncology | N/A | |
| Theresa Ferguson | Predictive Oncology | N/A | |
| Andrew CPA | Sharps Technology | 68 | |
| Adam III | Nexgel Inc | 47 | |
BioLife Sciences Management Team
Elected by the shareholders, the BioLife Sciences' board of directors comprises two types of representatives: BioLife Sciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BioLife. The board's role is to monitor BioLife Sciences' management team and ensure that shareholders' interests are well served. BioLife Sciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BioLife Sciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Nika Jaksic, COO Director | ||
| Colton Gooyer, Director Operations | ||
| Justin Four, CEO Founder |
BioLife Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is BioLife Sciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Current Valuation | 1.01 M | |||
| Price To Sales | 0 X | |||
| Net Income | (456.87 K) | |||
| Cash And Equivalents | 15.62 K | |||
| Total Debt | 398 K | |||
| Current Ratio | 0.07 X | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (106.55 K) | |||
| Earnings Per Share | (0.01) X | |||
| Beta | 0.0763 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in BioLife Pink Sheet
BioLife Sciences financial ratios help investors to determine whether BioLife Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BioLife with respect to the benefits of owning BioLife Sciences security.